# Toripalimab Combined With CAV/IE Regimen

> **NCT04589741** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 200 (estimated)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Toripalimab Combined With CAV/IE chemotherapy
- **DRUG:** CAV/IE alternate chemotherapy

## Key facts

- **NCT ID:** NCT04589741
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-23
- **Primary completion:** 2025-01-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04589741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04589741, "Toripalimab Combined With CAV/IE Regimen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04589741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*